<DOC>
	<DOC>NCT00372333</DOC>
	<brief_summary>The main aim of the study is to evaluate safety, efficacy, compliance, and usage of epicutaneously applied IDEA-033 in joint / musculoskeletal pain or soft tissue inflammation.</brief_summary>
	<brief_title>IDEA-033 Open Label Study</brief_title>
	<detailed_description>Multi-centre, one arm, multiple dose, open-label, at home usage study. Adult volunteers experiencing joint pain, musculoskeletal pain, stiffness, or soft tissue inflammation will be screened for study participation.</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Musculoskeletal Pain</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<criteria>at least 18 years or older agree to refrain from chronic usage of NSAIDs or any other analgesics or antiinflammatory drugs other than those provided during the course of the study or documented sporadic concomitant analgesics joint pain, musculoskeletal pain, stiffness, or soft tissue inflammation in designated target area(s) that are appropriate for selftreatment with a topical analgesic or where availability of a second person can be guaranteed in case selftreatment is not possible healthy skin in the target area(s) known hypersensitivity to IDEA033 or other NSAIDs history of coagulation disorders history of peptic ulcers or gastric intolerance with NSAIDs urinary tract infection clinically significant renal, hepatic, or gastric disease acute or chronic coexisting illness qualifying for exclusion according to clinical judgement of the investigator clinical laboratory values outside normal range deemed clinically significant by the investigator Narcoticscontaining products within 7 days of administering IMP Malignancy within the past 2 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>musculoskeletal pain; soft tissue inflammation; IDEA-033</keyword>
</DOC>